According to several cost-effectiveness analyses [11–13], most treatments in the HF landscape, including angiotensin-converting enzymes (ACE) inhibitors, beta-blockers, spironolactone, and several others, are considered cost-effective per the WHO and ACC/AHA definition. The gene discussed is ACE; the disease is hydrops fetalis.